First Trimester Screening Tests Pregnancy and Trisomy 13 Syndrome, Sex Chromosome Aneuploidy in Iran: A Cross-Sectional Study

Document Type : Original Article


1 Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran

2 Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran

3 Narges Genetics Diagnostic Laboratory, Ahvaz, Iran


Background: Trisomy 13 (T13) and sex chromosome aneuploidies (SCA) are the vital causes of congenital malformations. This study was performed to identify the T13 and SCA with screening tests in the first trimester of pregnancy.
Materials and Methods: In this cross-sectional study, first-trimester combined screening was conducted on 2100 pregnant women referred to Narges Genetics Laboratory, Ahvaz, Iran. Evaluating the first trimester screening tests, including nuchal translucency (NT), crown–rump length (CRL) and pregnancy-associated plasma protein-A (PAPP-A), and free beta of human chorionic gonadotropin (fβhCG) was performed. For a definitive diagnosis of T13 and SCA syndrome, fetal karyotype was evaluated.
Results: The average NT and CRL in high-risk group for T13 were 5.96 mm and 61.7 mm respectively and in high-risk groups for SCA were 3.7 mm and 75.9 mm, respectively. Significant correlation was observed among NT, CRL and T13, SCA (P<0.05). The average serum fβhCG and PAAP-A levels in high-risk group for T13 were 0.42 and 0.31, respectively. Significant correlation was observed between decrease fβhCG, PAPP-A and T13 levels and increase fβhCG levels and SCA levels (P<0.05). No Significant correlation was observed between PAPP-A levels and SCA levels (P>0.05).
Conclusion: Using special software and karyotype testing, the prenatal screening tests based on the maternal age and gestational age in the first trimester of pregnancy may determine the major risk of fetal chromosomal abnormalities.


Main Subjects

  1. Duque JAP, Ferreira CF, Zachia SA, Sanseverino MTV, Gus R, Magalhães JAA. The natural history of pregnancies with prenatal diagnosis of Trisomy 18 orTrisomy 13: retrospective cases of a 23-year experience in a Brazilian publichospital. Genet Mol Biol. 2019; 42 Suppl 1: 286-296.
  2. Deng C, Zhu Q, Liu S, Liu J, Bai T, Jing X, et al. Clinical application of noninvasive prenatal screening for sex chromosome aneuploidies in 50,301 pregnancies: initial experience in a Chinese hospital. Sci Rep. 2019; 9: 7767.
  3. Witters G, Van Robays J, Willekes C, Coumans A, Peeters H, Gyselaers W, et al. Trisomy 13, 18, 21, Triploidy and Turner syndrome: the 5T’s. Look at the hands. Facts Views Vis Obgyn. 2011; 3(1): 15-21.
  4. Zheng Y, Wan S, Dang Y, Song T, Chen B, Zhang J. Non-invasive prenatal testing for detection of trisomy 13, 18, 21 and sex chromosome aneuploidies in 8594 cases. Ginekol Pol. 2019; 90(5): 270-276.
  5. Yaron Y, Ochshorn Y, Tsabari S, Shira AB. First-trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A can detect triploidy and determine the parental origin. Prenat Diagn. 2004; 24: 445-450.
  6. Jezela-Stanek A, Krajewska-Walasek M. Noninvasive prenatal testing of aneuploidies: where are we now? Rev Bras Ginecol Obstet. 2014; 36(9): 383-386.
  7. Allen EG, Freeman SB, Druschel C, Hobbs CA, O’Leary LA, Romitti PA, et al. Maternal age and risk for trisomy.21 assessed by the origin of chromosome nondisjunction: a report from the atlanta and national down syndrome projects. Hum Genet. 2009; 125(1): 41-52.
  8. Malan V, Bussières L, Winer N, Jais JP, Baptiste A, Le Lorc'h M, et al. Effect of cell-free DNA screening vs direct invasive diagnosis on miscarriage rates in women with pregnancies at high risk of trisomy 21. JAMA. 2018; 320(6): 557-565.
  9. Morris JK, Savva GM. The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. Am J Med Genet A. 2008; 146A(7): 827-832.
  10. Kawasaki H, Yamada T, Takahashi Y, Nakayama T, Wada T, Kosugi S. The short-term mortality and morbidity of very low birth weight infants with trisomy 18 or trisomy 13 in Japan. J Hum Genet. 2020; 66(3): 273-285.
  11. Bringman JJ. Invasive prenatal genetic testing: a Catholic healthcare provider's perspective. Linacre Q. 2014; 81(4): 302-313.
  12. Syngelaki A, Guerra L, Ceccacci I, Efeturk T, Nicolaides KH. Impact of holoprosencephaly, exomphalos, megacystis and high NTT in first trimester screening for chromosomal abnormalities. Ultrasound Obstet Gynecol. 2017; 50(1): 45-48.
  13. Dolatkhah M, Noori S, Khavari-Nejad RA, Rahnamaye Farzami M. First-trimester combined screening for trisomies 21, 18, and 13 by three closed chemiluminescence immunoassay analyzers (an experiment on Iranian pregnant women). Iran J Neonatol. 2020; 11(3): 71-79.
  14. Catic A, Gurbeta L, Kurtovic-Kozaric A, Mehmedbasic S, Badnjevic A. Application of neural networks for classification of patau, edwards, down, turner and klinefelter syndrome based on first trimester maternal serum screening data, ultrasonographic findings and patient demographics. BMC Med Genomics. 2018; 11(1): 19.
  15. Palomaki GE, Lee JE, Canick JA, McDowell GA, Donnenfeld AE. Technical standards and guidelines: prenatal screening for Down syndrome that includes first-trimester biochemistry and/or ultrasound measurements. Genet Med. 2009; 11(9): 669-681.
  16. Guex N, Iseli C, Syngelaki A, Deluen C, Pescia G, Nicolaides KH, et al. A robust 2nd generation genome-wide test for fetal aneuploidy based on shotgun sequencing cell-free DNA in maternal blood. Prenat Diagn. 2013; 33(7): 707-710.
  17. Shiefa S, Amargandhi M, Bhupendra J, Moulali S, Kristine T. First trimester maternal serum screening using biochemical markers PAPP-A and free b-hCG for down syndrome, patau syndrome and edward syndrome. Ind J Clin Biochem. 2013; 28(1): 3-12.
  18. Shahshahan Z, Azami N. The diagnostic value of combined test for trisomy 21 and 18 screening in over 35-years old pregnant women in the gestational age of 9-14 Weeks. J Isfahan Med Sch. 2013; 30: 400-407.
  19. Hawk AF, Saller DN. Screening for fetal aneuploidy: is maternal age relevant? Clin Obstet Gynecol. 2012: 55(1): 217-225.
  20. Seyyedkavoosi E, Younessi S, Farhud D. Screening of fetal chromosome aneuploidies in the first and second trimester of 125,170 Iranian pregnant women. Iran J Public Health. 2015; 44(6): 791-796.
  21. Xue S, Yan H, Chen J, Li N, Wang J, Liu Y, et al. Genetic examination for fetuses with increased fetal nuchal translucency by genomic technology. Cytogenet Genome Res. 2020; 160(2): 57-62.
  22. Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH. Screening for trisomy's 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A. Hum Reprod. 2008; 23(9): 1968-1975.
    23. Huang T, Dennis A, Meschino WS, Rashid S, Mak-Tam E, Cuckle H. First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-β human chorionic gonadotrophin, placental growth factor, and α-fetoprotein. Prenat Diagn. 2015; 35(7): 709-716.
    24. Carrara J, Vivanti A, Jani JC, Demain A, Costa J, Benachi A. Usefulness and reliability of cell free fetal DNA screening for main trisomies in case of atypical profile on first serum screening. J Transl Med. 2019; 1(1): 398.
    25. Engell AE, Carlsson ER, Jørgensen FS, Sørensen S. Comparison of two immunoassay systems for hCGβ and PAPP-A in prenatal screening for trisomy 21, 18, and 13 in the first trimester. Pract Lab Med. 2017; 9: 18-23.
    26. Karaaslan O, Seckin KD, Kadirogullari P, Kiyak H, Bestel M, Simsek E, et al. The utility of pregnancy associated plasma protein-A MoM values in prediction of term respiratory distress syndrome. J Obstet Gynaecol. 2020; 40(2): 200-204.
    27. Spencer K. Aneuploidy screening in the first trimester Am J Med Genet C Semin Med Genet. 2007; 145C(1): 18-32.
    28. Piazze J, Anceschi MM, Cerekja A, La Torre R, Pala A, Papa A, et al. Nuchal translucency as a predictor of adverse pregnancy outcome. Int J Gynaecol Obstet. 2007; 98(1): 5-9.
    29. Kolarski M, Ahmetovic B, Beres M, Topic R, Nikic V, Kavecan I, et al. Genetic counseling and prenatal diagnosis of triploidy during the second trimester of pregnancy. Med Arch. 2017; 71(2): 144-147.
    30. Hai Long N, Danh Cuong T, Toan Anh N. Relation between increased fetal Nuchal translucency thickness and chromosomal defects in northern Vietnam. Cureus. 2021; 13(10): e18446.
    31. Xue SH, Yan H, Chen J, Li N, Wang J, Liu Y. genetic examination for fetuses with increased fetal nuchal translucency by genomic technology. Cytogenet Genome Res. 2020; 160(2): 1-6.
    32. Younesi S, Taheri Amin MM, Hantoushzadeh S, Saadati P, Jamali S, Modarressi MH, et al. Karyotype analysis of amniotic fluid cells and report of chromosomal abnormalities in 15,401 cases of Iranian women. Sci Rep. 2021; 11(1): 19402.
    33. Mak A, Lee H, Poon CF, Kwok SL, Ma T, Chan KYK, et al. Factors associated with common and atypical chromosome abnormalities after positive combined first-trimester screening in Chinese women: a retrospective cohort study. BMC Pregnancy Childbirth. 2019; 19(1): 55.
    34. Viuff MH, Stochholm K, Uldbjerg N, Nielsen BB; Danish Fetal Medicine Study Group, Gravholt CH. Only a minority of sex chromosomeabnormalities are detected by anational prenatal screening programfor down syndrome. Hum Reprod. 2015; 30(10): 2419-2426.
    35. Maymon R, Sharony R, Grinshpun-Cohen J, Itzhaky D, Herman A, Reish O. The best marker combination using the integrated screening test approach for detecting various chromosomal aneuploidies. J Perinat Med. 2005; 33(5): 392-398.
    36. Kazemi M, Salehi M, Kheirollahi M. Down syndrome: current status, challenges and future perspectives. Int J Mol Cell Med. 2016; 5(3): 125-133.
    36. Wright D, Syngelaki A, Bradbury L, Akolekar R, Nicolaides KH. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagn Ther. 2014; 35(2): 118-126.
    38. Lu X, Wang C, Sun Y, Tang Y, Tong K, Zhu J. Noninvasive prenatal testing for assessing foetal sex chromosome aneuploidy: a retrospective study of 45,773 cases. Mol Cytogenet. 2021; 14(1): 1.